title: A longitudinal assessment of the effect of inhaled fluticasone propionate therapy on adrenal function and growth in young children with asthma.
abstract: OBJECTIVE
  Fluticasone proprionate (FP) is increasingly used to treat very young children with asthma. Its safety in terms of effects on the hypothalamic pituitary axis (HPA) and growth in this age group is uncertain.
  
  
  METHODS
  Eleven children (median (range) age 10 (5.6-24.3) months) presenting with recurrent wheeze and family history of asthma were studied prospectively for a period of 18 months. Children received daily-inhaled FP 250 microg via a spacer device. No other corticosteroid therapy was administered prior to or during the study. A Short Standard Synacthen Test (SST) (125 microg) was performed pretreatment, and after 6 and 18 months. Weight (Wt), height (Ht), and body mass index (BMI) were measured at 3-6 monthly intervals.
  
  
  RESULTS
  Fasting early morning and peak cortisol levels remained within the normal reference range with therapy. There were no changes in Ht SDS, whereas both Wt SDS (baseline 0.05 (-2.17 to 0.52) vs. +18 months 0.68 (-0.5 to 1.36) P < 0.02) and BMI SDS (-0.22 (-1.73 to 0.75) vs. 0.86 (0.03 to 1.99) P < 0.005) increased after 18 months of treatment.
  
  
  CONCLUSIONS
  Daily treatment with inhaled FP 250 microg in young children with asthma appears to have no adverse effects on the HPA or on linear growth, however, treatment is associated with increases in body Wt and BMI in young children.
authors.affiliation: Department of Paediatrics, Addenbrooke's NHS Trust, Cambridge, UK. richard.iles@addenbrookes.nhs.uk
authors.forename: R
authors.initials: R
authors.lastname: Iles
authors.forename: R M
authors.initials: RM
authors.lastname: Williams
authors.forename: R W
authors.initials: RW
authors.lastname: Williams
authors.forename: A
authors.initials: A
authors.lastname: Deeb
authors.forename: R
authors.initials: R
authors.lastname: Ross-Russell
authors.forename: C L
authors.initials: CL
authors.lastname: Acerini
mesh_terms: D000280:Administration, Inhalation; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D001827:Body Height / Q000187:drug effects*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002657:Child Development / Q000187:drug effects; D002675:Child, Preschool; D015331:Cohort Studies; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects*; D007223:Infant; D008137:Longitudinal Studies; D008297:Male; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011446:Prospective Studies; D012135:Respiratory Sounds / Q000187:drug effects
chemical_list: D000730:Androstadienes; D015415:Biomarkers; D001993:Bronchodilator Agents; D000068298:Fluticasone; D006854:Hydrocortisone